PubRank

Stefano Perlini

Author PubWeight™ 41.49‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Circulating amyloidogenic free light chains and serum N-terminal natriuretic peptide type B decrease simultaneously in association with improvement of survival in AL. Blood 2006 1.95
2 Systemic cardiac amyloidoses: disease profiles and clinical courses of the 3 main types. Circulation 2009 1.93
3 Serum N-terminal pro-brain natriuretic peptide is a sensitive marker of myocardial dysfunction in AL amyloidosis. Circulation 2003 1.93
4 Disease profile and differential diagnosis of hereditary transthyretin-related amyloidosis with exclusively cardiac phenotype: an Italian perspective. Eur Heart J 2012 1.77
5 [Hypertensive heart disease: diagnostic and therapeutic guidelines]. G Ital Cardiol (Rome) 2008 1.39
6 The combination of thalidomide and intermediate-dose dexamethasone is an effective but toxic treatment for patients with primary amyloidosis (AL). Blood 2004 1.30
7 The combination of high-sensitivity cardiac troponin T (hs-cTnT) at presentation and changes in N-terminal natriuretic peptide type B (NT-proBNP) after chemotherapy best predicts survival in AL amyloidosis. Blood 2010 1.27
8 A phase II trial of cyclophosphamide, lenalidomide and dexamethasone in previously treated patients with AL amyloidosis. Haematologica 2012 1.10
9 Effects of tafamidis on transthyretin stabilization and clinical outcomes in patients with non-Val30Met transthyretin amyloidosis. J Cardiovasc Transl Res 2013 1.09
10 Prevention of recurrent lone atrial fibrillation by the angiotensin-II converting enzyme inhibitor ramipril in normotensive patients. J Am Coll Cardiol 2009 1.08
11 Distinct mechanisms for diastolic dysfunction in diabetes mellitus and chronic pressure-overload. Basic Res Cardiol 2011 1.05
12 Cardiovascular risk assessment in low-resource settings: a consensus document of the European Society of Hypertension Working Group on Hypertension and Cardiovascular Risk in Low Resource Settings. J Hypertens 2014 1.04
13 Increased prevalence of metabolic syndrome in uncontrolled hypertension across Europe: the Global Cardiometabolic Risk Profile in Patients with hypertension disease survey. J Hypertens 2008 1.00
14 Unusual manifestations of disseminated neoplasia at presentation: right-sided heart failure due to a massive cardiac metastasis and autoimmune thrombocytopenia in pleomorphic rhabdomyosarcoma of the adult. Am J Clin Oncol 2006 0.98
15 Treatment of patients with advanced cardiac AL amyloidosis with oral melphalan, dexamethasone, and thalidomide. Ann Hematol 2008 0.97
16 Prevention of myocardial fibrosis by N-acetyl-seryl-aspartyl-lysyl-proline in diabetic rats. Clin Sci (Lond) 2009 0.96
17 The repertoire of λ light chains causing predominant amyloid heart involvement and identification of a preferentially involved germline gene, IGLV1-44. Blood 2011 0.95
18 Oral melphalan and dexamethasone grants extended survival with minimal toxicity in AL amyloidosis: long-term results of a risk-adapted approach. Haematologica 2013 0.92
19 Blood pressure control and components of the metabolic syndrome: the GOOD survey. Cardiovasc Diabetol 2009 0.91
20 Doxycycline plus tauroursodeoxycholic acid for transthyretin amyloidosis: a phase II study. Amyloid 2012 0.89
21 Hypertension and acute myocardial infarction: an overview. J Cardiovasc Med (Hagerstown) 2012 0.88
22 Right ventricular function in AL amyloidosis: characteristics and prognostic implication. Eur Heart J Cardiovasc Imaging 2011 0.84
23 Gender-related risk of myocardial involvement in systemic amyloidosis. Amyloid 2008 0.84
24 Lobe-specific heterogeneity and matrix metalloproteinase activation after ischemia/reperfusion injury in rat livers. Toxicol Pathol 2012 0.83
25 Matrix metalloprotease activity is enhanced in the compensated but not in the decompensated phase of pressure overload hypertrophy. Am J Hypertens 2007 0.82
26 Cardiac mast cells in the transition to heart failure: innocent bystanders or key actors? J Hypertens 2003 0.81
27 Preservation of the baroreceptor heart rate reflex by chemical sympathectomy in experimental heart failure. Circulation 2002 0.81
28 Midregional proadrenomedullin (MR-proADM) is a powerful predictor of early death in AL amyloidosis. Amyloid 2011 0.80
29 Hypertension-related target organ damage: is it a continuum? J Hypertens 2013 0.80
30 Peripheral blood progenitor cell mobilization and collection in 42 patients with primary systemic amyloidosis. Transfusion 2005 0.80
31 Best use of cardiac biomarkers in patients with AL amyloidosis and renal failure. Am J Hematol 2012 0.80
32 Echocardiographic and biohumoral characteristics in patients with AL and TTR amyloidosis at diagnosis. Clin Cardiol 2015 0.79
33 From hypertension to hypertrophy to heart failure: the role of cardiotrophin-1. J Hypertens 2013 0.78
34 Determinants of left ventricular mass in hypertensive heart disease: a complex interplay between volume, pressure, systolic function and genes. J Hypertens 2007 0.78
35 Cost-effectiveness in Italy of preventive treatment with ramipril in patients at high risk of cardiovascular events. Curr Med Res Opin 2005 0.78
36 Direct renin inhibition: another weapon to modulate the renin-angiotensin system in postinfarction remodeling? Hypertension 2008 0.77
37 Diagnostic and prognostic value of low QRS voltages in cardiac AL amyloidosis. Ann Noninvasive Electrocardiol 2013 0.76
38 An update on hypertensive emergencies and urgencies. J Cardiovasc Med (Hagerstown) 2015 0.76
39 Adenosine A1 and A2A receptor cross-talk during ageing in the rat myocardium. Exp Gerontol 2003 0.76
40 Prevalence and prognostic value of conduction disturbances at the time of diagnosis of cardiac AL amyloidosis. Ann Noninvasive Electrocardiol 2013 0.75
41 Electrocardiographic 'strain' pattern in left ventricular hypertrophy: electrical waves or mechanical function? J Hypertens 2006 0.75
42 The potential advantage of omapatrilat: dual anti-fibrotic and anti-inflammatory effects in one single molecule. J Hypertens 2005 0.75
43 As we cannot afford to renounce to new generation echocardiography in systemic amyloidosis. Amyloid 2013 0.75
44 Importance of the echocardiographic evaluation of right ventricular function in patients with AL amyloidosis. Eur J Heart Fail 2007 0.75
45 [Role of ACE-inhibitors in preventing atrial fibrillation relapses in normotensive patients]. Recenti Prog Med 2009 0.75
46 Vascular alterations in apolipoprotein A-I amyloidosis (Leu75Pro). A case-control study. Amyloid 2015 0.75
47 A multimarker study of degenerative aortic valve disease: stenoinsufficiency shows more indices of bad prognosis. Cardiology 2013 0.75
48 Early development of metabolic syndrome in patients subjected to lung transplantation. Clin Transplant 2013 0.75
49 High 99mTc-DPD myocardial uptake in a patient with apolipoprotein AI-related amyloidotic cardiomyopathy. Amyloid 2012 0.75
50 Hypertension and stable coronary artery disease: an overview. J Cardiovasc Med (Hagerstown) 2013 0.75